| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5583122 | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) | |
|
US5583122 (Pediatric) | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Jun, 2014
(9 years ago) | |
| US6165513 | APIL | Film-coated tablet for improved upper gastrointestinal tract safety |
Jun, 2018
(5 years ago) | |
| US6432932 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6015801 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US5994329 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6465443 | APIL | Method for inhibiting bone resorption |
Aug, 2018
(5 years ago) | |
|
US6165513 (Pediatric) | APIL | Film-coated tablet for improved upper gastrointestinal tract safety |
Dec, 2018
(5 years ago) | |
|
US5994329 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6432932 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6015801 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6465443 (Pediatric) | APIL | Method for inhibiting bone resorption |
Feb, 2019
(5 years ago) | |
| US7718634 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
| US7192938 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
|
US7718634 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(5 months ago) | |
|
US7192938 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(5 months ago) | |
Actonel is owned by Apil.
Actonel contains Risedronate Sodium.
Actonel has a total of 16 drug patents out of which 16 drug patents have expired.
Expired drug patents of Actonel are:
- US5583122
- US5583122*PED
- US6165513
- US6432932
- US6015801
- US5994329
- US6465443
- US6165513*PED
- US5994329*PED
- US6432932*PED
- US6015801*PED
- US6465443*PED
- US7718634
- US7192938
- US7718634*PED
- US7192938*PED
Actonel was authorised for market use on 14 April, 2000.
Actonel is available in tablet;oral dosage forms.
Actonel can be used as treatment of osteoporosis in postmenopausal women, 35 mg orally once a week for prevention of osteoporosis in postmenopausal women; 35 mg orally once a week for treatment of osteoporosis in postmenopausal women, method of treating paget's disease using actonel, prevention and treatment of osteoporosis.
The generics of Actonel are possible to be released after 06 November, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 23, 2012 |
| Pediatric Exclusivity(PED) | Jan 23, 2013 |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 14 April, 2000
Treatment: Method of treating paget's disease using actonel; 35 mg orally once a week for prevention of osteoporosis in postmenopausal women; 35 mg orally once a week for treatment of osteoporosis in postmenopau...
Dosage: TABLET;ORAL
ACTONEL family patents
